Trial Profile
Does Immune-modulation Improve the Survival in Patients With Severe Sepsis? 'A Proof of the Concept Study'
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Mycobacterium smegmatis vaccine (Primary)
- Indications Sepsis; Septic shock
- Focus Therapeutic Use
- Acronyms MISS
- 29 Jan 2014 New trial record